Approval · Notice of Compliance 9751 · 2008
ALIMTA: Notice of Compliance 9751
Issued September 2, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9751
- Date
- September 2, 2008
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: in combination with cisplatin therapy is indicated for the initial treatment of good performance status patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALIMTA | Not yet assigned | — |
Medicinal ingredients
- PEMETREXED DISODIUM 500 MG per VIAL
- PEMETREXED DISODIUM 100 MG per VIAL